Jon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn:
“Important new IO solid tumor insight in NEJM + presented at ESMO.
T-cell engager (Tarlatamab) in combination with checkpoint inhibitor (Durvalumab) markedly enhances both PFS and OS versus checkpoint inhibitor alone in maintenance setting for patients with extensive-stage small cell lung carcinoma (ES-SCLC).
OS 21.1 vs 12.7 mos (HR=0.42, P<0.001). PFS 7.4 vs 1.9 mos (HR=0.34, P<0.001). Grade 3 or greater AE 46.8% in combo pts vs 40.6% of patients treated with Durvalumab alone. TCEs can also drive the PD-1/PD-L1 axis, so this combination makes good sense. Important concept for IO-IO combination therapy.”
Title: Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
Authors: Maurice Pérol, Tatsuya Yoshida, Myung-Ju Ahn, Carl M. Gay, Martin Schuler, Haifeng Liu, Ahmet Sezer, Ahmet Bilici, Ippokratis Korantzis, Sun Min Lim, Kohei Otsubo, Oscar Juan-Vidal, Yuanbin Chen, Gustavo Schvartsman, Haiyong Wang, Anne-Marie C. Dingemans, Jeffrey M. Clarke, Aakash Desai, Miguel Marigil, Yuqi Chen, Bazle Abidi, Jessie Wang, and Jacob Sands, for the DeLLphi-305 Investigators.
Read the full article.
The ESMO Congress 2026 is the annual meeting of the European Society for Medical Oncology. It stands as one of the world’s most influential oncology platforms for presenting pioneering cancer research. The event takes place from October 23 to 27, 2026, in Madrid, Spain, at the IFEMA MADRID convention center, utilizing a highly accessible hybrid (in-person and virtual) format.
Learn more about ESMO 2026.
You may also be interested in: DeLLphi-305: Tarlatamab–Durvalumab Redefines First-Line Maintenance in Extensive-Stage SCLC
